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Human immunodeficiency virus type 1 (HIV-1) infection often results in disorders of the central nervous system, including
HIV-associated dementia (HAD). It is suspected that tumor necrosis factor- (TNF) released by activated and/or infected
macrophages/microglia plays a role in the process of neuronal damage seen in AIDS patients. In light of earlier studies
showing that the activation of the insulin-like growth factor I receptor (IGF-IR) exerts a strong neuroprotective effect, we
investigated the ability of IGF-I to protect neuronal cells from HIV-infected macrophages. Our results demonstrate that the
conditioned medium from HIV-1-infected macrophages, HIV/CM, causes loss of neuronal processes in differentiated PC12
and P19 neurons and that these neurodegenerative effects are associated with the presence of TNF. Furthermore, we
demonstrate that IGF-I rescues differentiated neurons from both HIV/CM and TNF-induced damage and that IGF-I-mediated
neuroprotection is strongly enhanced by overexpression of the wt IGF-IR cDNA and attenuated by the antisense IGF-IR
cDNA. Finally, IGF-I-mediated antiapoptotic pathways are continuously functional in differentiated neurons exposed to
HIV/CM and are likely supported by TNF-mediated phosphorylation of IB. All together these results suggest that the
balance between TNF and IGF-IR signaling pathways may control the extent of neuronal injury in this HIV-relatedKey Words: HIV associated dementia; neuronal damage
INTRODUCTION
Human immunodeficiency virus (HIV) infection often
involves clinical manifestations including cognitive motor
disorders as well as behavioral and cognitive abnormal-
ities, which are observed in at least two-thirds of AIDS
patients (Gabuzda and Hirsch, 1987). The brains at au-
topsy often exhibit microglial nodules containing
multinucleated giant cells, increased numbers of
perivascular macrophages, and activated macrophages/
microglia in brain parenchyma (Budka et al., 1987). Al-
though monocyte and T cell infiltration of the central
nervous system appears relatively early during HIV in-
fection, and the initial invasion is usually cleared, neu-
rological changes occur much later during the course of
the disease. Therefore, the presence of HIV-infected
cells within the brain tissue may not be the sole cause of
neuronal cell dysfunction and death (Price, 1988; Price et
al., 1988). During the course of HIV infection, macro-
phages/microglia, as well as other cells in the brain, can
be exposed to viral proteins such as gp120 and Tat. This
in turn may activate expression and secretion of several
cytokines, including tumor necrosis factor- (TNF),004
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which via auto- or paracrine mechanisms may dysregu-
late even further metabolism in the brain tissue (Rieck-
mann et al., 1991; Rimaniol et al., 1997). TNF mRNA and
protein expression are increased in HIV-induced neuro-
logical disorders (Kaul and Lipton, 1999; Sippy et al.,
1995; Tan et al., 1996). In addition to the deleterious
effects of TNF production, neuronal injury may be fur-
ther promoted by parallel decreases in neuroprotective
factors. In HIV patients with wasting syndrome and in
children with Failure to Thrive (FTT), reduced insulin-like
growth factor I (IGF-I) serum levels have been reported
(Jain et al., 1998; Laue et al., 1990).
The receptor for IGF-I (IGF-IR) is a membrane-associ-
ated multifunctional tyrosine kinase with activities in
many cell types, including cells from the central nervous
system. IGF-IR signaling protects neurons from ischemic
injuries (Gluckman et al., 1992), inhibits low potassium-
induced apoptosis of cerebellar granule neurons
(D’Mello et al., 1993), and rescues brain tumor cell lines
from apoptosis induced by anchorage-independent cul-
ture conditions (Wang et al., 2001). At least three path-
ways may contribute to the IGF-IR-mediated cell protec-
tion from apoptotic death. Two of these pathways de-
pend upon Akt activation and may result in Bad (Peruzziexperimental setting. © 2002 Elsevier Science (USA)
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to counteract apoptosis. The third pathway, in contrast,
appears to be Akt-independent and results in Raf phos-
phorylation and its translocation to the mitochondrial
compartment (Peruzzi et al., 2001).
Similar to IGF-I, TNF induces a broad range of bio-
logical events (Locksley et al., 2001). TNF is an inflam-
matory cytokine produced by activated macrophages
and other cell types, including lymphocytes, hepatocytes,
and fibroblasts (Natoli et al., 1998; Wallach, 1997). It binds
with high affinity and activates two receptors, TNFR1 and
TNFR2, which belong to a large superfamily including
more than 20 surface proteins involved in a variety of
biological responses including host defense, inflamma-
tion, apoptosis, and differentiation (Locksley et al., 2001).
Although TNFR2 is able to activate some cellular re-
sponses mostly in hematopoietic cells, the TNFR1 is
thought to be the major receptor responsible for TNF
signaling in the majority of cells including neurons (Gary
et al., 1998; Natoli et al., 1998). The receptor does not
reveal any known enzymatic activities; however, it en-
gages into signaling pathways by recruiting other adap-
tor proteins. Following ligand binding, receptor mole-
cules trimerize creating internal complexes with signal-
ing proteins such as TNFR-associated death domain
containing protein (TRADD), TNFR-associated factor 2
(TRAF2) and/or Fas-associated death domain protein
(FADD) (Natoli et al., 1998). Present understanding of the
signaling events includes TRADD recruitment into C-
terminus of TNFR1 and subsequent binding of FADD,
TRAF2, and/or receptor interacting protein (RIP) into the
complex. Depending on the circumstances, which are
not well defined and could depend on the activation of
other growth factor receptors and/or availability of the
substrate(s), the TNFR1 receptor may send contradictory
signals. The first one is antiapoptotic and involves pref-
erential binding of TRAF2 into ligand-activated receptor.
Two signaling branches can diverge from here: NFB
translocation to the nucleus (Lieberson et al., 2001) and
JNK/p38-mediated phosphorylation of transcription fac-
tors including AP-1, ATF-2, and Elk (Boone et al., 1998;
Yuasa et al., 1998). Both pathways lead to the rearrange-
ment of the transcriptional activity of the cell, which in
turn could render resistance to apoptosis via expression
of antiapoptotic molecules such as FLIPs (Micheau et al.,
2001) and IAPs (Furusu et al., 2001). The second one is
purely proapoptotic and involves predominant recruit-
ment of FADD, its direct association with the CARD
(caspase recruitment domain) of caspase 8 or caspase
10 (initiators), and subsequent cleavage and activation of
executioner caspases 3, 6, and 7, leading to apoptotic
death of the cell (Boone et al., 2000; Kubota et al., 2001).
Since IGF-IR and TNFR1 may affect neuronal function
and survival by engaging opposing signaling pathways,
here we evaluate the contribution of TNF and IGF-I in
determining the fate of differentiated neurons upon ex-
posure to the conditioned medium from HIV-infected
macrophages. Our results demonstrate that in the ab-
sence of IGF-I stimulation, TNF strongly contributes to
the neuronal damage inflicted by the conditioned me-
dium from HIV-infected macrophages (HIV/CM). IGF-I
treatment rescues differentiated neurons from both
HIV/CM and TNF-induced damage, and the neuropro-
tection is proportional to the level of IGF-IR expression in
the affected neurons. In the presence of IGF-I differenti-
ated neurons retain the ability to survive the treatment
with HIV/CM by activating antiapoptotic molecules from
the IGF-IR.
RESULTS
Neurotoxic effect of the conditioned medium from
HIV-infected macrophages (HIV/CM)
We have utilized differentiated cultures of PC12 and
P19 neurons to evaluate potential toxic effects of the
conditioned medium collected from HIV-infected macro-
phages (HIV/CM). P19 mouse teratocarcinoma cells pro-
liferate in the absence of the differentiation signal and
can be efficiently transduced with retroviral expression
vectors. Treatment of the cells with retinoic acid results
in the expression of neuronal cell markers and the de-
velopment of axon-like and dendrite-like cellular pro-
cesses (Jones-Villeneuve et al., 1982). Treatment of dif-
ferentiated P19 or PC 12 neurons with HIV/CM caused a
drastic difference in the morphology of the cells. Shown
in Fig. 1 are representative morphological changes in
differentiated cultures of P19 cells before (A and B) and
at 72 h following treatment with either the HIV/CM (D) or
with the control conditioned medium (CCM) (C). Note that
images in Figs. 1A and 1B and images in Figs. 1C and 1D
were taken from the same microscopic fields at two
different time points, respectively. Figure 1 also demon-
strates representative alterations in PC 12 cells upon the
treatment with CCM (compare Figs. 1E and 1G) or
HIV/CM (compare Figs. 1F and 1H). The quantitative
assessment of the observed differences for PC 12 and
P19 cells is shown in Figs. 1I and 1J, respectively. We
have determined the baseline for the number of the
neurite-bearing cells present in three randomly chosen
microscopic fields per plate at 3 days after NGF treat-
ment (TO). The number of neurite-bearing cells in the
same microscopic fields was monitored at 24 and 96 h
after the HIV/CM treatment. In the absence of the con-
ditioned media (No CM), the number of PC 12 cells
bearing cellular processes increased with time. In con-
trast, a dose- and time-dependent decrease in the num-
ber of differentiated neurons was observed following the
treatment with increasing concentrations of the HIV/CM.
Although control conditioned medium (CCM) collected
from uninfected macrophages also affected the number
of neurite-bearing cells, the effects were much less pro-
nounced than those seen upon exposure of the cells to
HIV/CM. Since the observed difference between HIV/CM
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and CCM at the 1:5 dilution (1 vol of the HIV/CM or CCM
and 4 vol of the fresh culture medium) was highly signif-
icant (P  0.001), this condition was used throughout
the next series of experiments. Similar to PC 12, a mas-
sive neuronal loss was detected in differentiated cul-
tures of P19 cells upon treatment with HIV/CM. These
cells appear to be particularly sensitive to HIV/CM since
a substantial loss of the neuronal processes was noticed
as early as 24 h after the treatment, and virtually all
differentiated P19 cells were lost within 72 h (Fig. 1J). In
contrast, examination of the effects of HIV/CM on undif-
ferentiated monolayer cultures of PC 12 and P19 cells
revealed no significant effects on the cell death, as
determined by the TUNEL assay and by counting of the
cell number. Following the treatment, HIV/CM 1:5 dilution
for 48 h, only 0.27% (0.04) of P19 cells and 0.15% (0.05)
of PC12 cells show a positive labeling for DNA strand
breaks. In control conditions, C/CM, 1:5 dilution for 48 h,
the values were similar, showing 0.22% (0.01) and 0.1%
(0.02) of apoptotic cells, respectively.
Opposing effects of TNF and IGF-I on
HIV/CM-mediated neuronal damage
To evaluate a potential contribution of TNF in HIV-
mediated neuronal cell damage, we utilized the ap-
proach in which the conditioned medium (HIV/CM) was
pretreated with the antibody against TNF. As shown in
Fig. 2A, preincubation with anti-TNF neutralizing anti-
body at 0.1 g/ml for 2 h efficiently neutralized in a dose
dependent manner toxicity of the HIV/CM. Conversely,
addition of the recombinant TNF, 20 ng/ml, into the
FIG. 2. Contribution of TNF and IGF-I to HIV/CM-mediated neuronal damage. (A) Differentiated P19 cells were exposed either to HIV/CM or to
control conditioned medium (CCM) both at 1:5 dilution with the fresh culture medium. In some samples, HIV/CM was modified by 2 h preincubation
with increasing concentrations (from 0.01 to 0.5 g/ml) of the anti-TNF neutralizing antibody (R&D Systems; AF-210-NA). To imitate neurotoxic action
of the HIV/CM, differentiated P19 cells were also treated with the recombinant TNF (20 ng/ml). All other parameters of the experiment are described
in the legend to Fig. 1. (B) P19 cells differentiated by retinoic acid were treated with IGF-I (50 ng/ml), TNF (20 ng/ml), and the combination of either
IGF-I and TNF or IGF-I and HIV/CM (1:5 dilution). The results represent percentage change in an average length of neuronal processes in
comparison to measurements taken before the treatment. This is an average of two experiments consisting of two 35-mm plates per data point, from
which measurements were taken in three separate microscopic fields (n  12).
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fresh medium markedly enhanced loss of neuronal pro-
cesses in differentiated cultures of P19 cells, further
supporting a role of this inflammatory cytokine in the
HIV-mediated neuronal damage. To determine if activa-
tion of the IGF-I receptor restores and/or promotes for-
mation of neuronal processes, P19 cells were cultured in
media containing IGF-I (50 ng/ml). As shown in Fig. 2B, it
is evident that IGF-I facilitates retinoic acid induced for-
mation of neuronal processes in P19 cells and that the
neurotoxic effects of HIV/CM and TNF are substantially
reduced in cells treated with IGF-I.
In the next set of experiments, we evaluated the ability
of IGF-IR to enhance IGF-I-mediated neuronal cell pro-
tection. In parallel, we have evaluated the ability of anti-
sense IGF-IR cDNA to suppress IGF-I-dependent neuro-
nal outgrowth and to sensitize cells to neurodegenera-
tive effects of the HIV/CM. We have generated stable cell
lines by transducing P19 cells with retrovirus vectors
expressing human IGF-R cDNA in sense or antisense
orientations. To avoid clonal variability, mixed popula-
tions of transduced cells were collected and utilized in
the study. Figure 3A indicates the levels of IGF-IR (top)
and TNFR1 (bottom) in parental P19 cells, in P19 cells
stably transduced with the wild-type IGF-IR cDNA (P19/
IGF-IR), in cells expressing antisense IGF-IR cDNA (P19/
aslGF-IR), and in control R600 fibroblasts, which express
3  104 IGF-IR molecules per cell (Reiss et al., 1998).
Densitometric assessment revealed that P19/IGF-IR cells
are characterized by a threefold increase in the IGF-IR
protein level when compared with the parental P19 cells.
Conversely, more than 50% decrease in the level of
IGF-IR was detected upon transducing cells with a ret-
rovirus vector expressing antisense IGF-IR. The same
blot was utilized to examine the level of housekeeping
gene product, GRB-2, to verify equal loading of the pro-
teins in various samples. The observed differences in the
levels of IGF-IR in transduced cell populations correlated
with the growth responses of the cells to IGF-I, as de-
termined by anchorage-independence assays. This as-
say is useful for evaluating the protective effects of IGF-I
under conditions where the ability of cells to interact with
extracellular matrix is restricted (Valentinis et al., 1998).
Under these conditions parental P19 cells exhibited a
modest ability to proliferate in response to IGF-I (Fig. 3B).
As expected, P19/IGF-IR cell proliferation was noticeably
improved in anchorage-independence, and the cells in
which the endogenous IGF-IR level was reduced due to
the expression of antisense IGF-IR cDNA lost the ability
to respond with cell proliferation following the IGF-I stim-
ulation. The cells, which were utilized in the above ex-
periments, were further analyzed for the protective ef-
fects of IGF-I. As mentioned above, differentiated P19
cells lose neuronal processes after the treatment with
HIV/CM (Fig. 1), and the addition of IGF-I substantially
protected their neuron-like phenotype (Fig. 2B). As illus-
trated in Fig. 3C, sensitivity of the cells to HIV/CM is
greatly increased upon the down-regulation of the en-
dogenous IGF-IR with the antisense cDNA (P19/asIGF-IR
cells). In contrast, P19 cells which ectopically overex-
press IGF-IR become resistant to the deleterious effects
of the HIV/CM upon the treatment with IGF-I (50 ng/ml).
Altogether, these observations strongly support the hy-
pothesis that activated IGF-I system confers protection
against neurotoxins present in the conditioned medium
of HIV-infected macrophages.
Effects of the HIV/CM on immediate signaling
responses from the IGF-IR
To evaluate whether the IGF-IR signaling pathways are
affected by HIV/CM, we investigated phosphorylation
levels for three signaling molecules (Akt, ERKs, GSK-3)
that are known to be activated by IGF-I stimulation and,
further, suggested to play a role in neuronal differentia-
tion and neuronal survival (Dudek et al., 1997; Yuan and
Yankner, 2000; Zheng et al., 2000). In these studies, IGF-I
stimulation was applied to retinoic acid differentiated
P19 cells. Results in Fig. 4 demonstrate that in serum-
free medium (SFM), P19 cells exhibit basal levels of
phosphorylation of GSK-3p, Akt, and Erk-2. Under the
same culture conditions, Erk-1 phosphorylation was not
detected. Within 15 min following IGF-I stimulation (IGF-
I), both phospho-GSK-3 and phospho-Akt were signifi-
cantly increased; phospho-Erk-2 was not affected and
phospho-Erk-1 remained undetectable. Having estab-
lished basal and induced levels of phosphorylation in
response to IGF-I in differentiated P19 cells, we exam-
ined whether pretreatment of the cells with the HIV/CM
affects the phosphorylation levels of these signaling mol-
ecules. First of all HIV/CM by itself did not affect basal
levels of the phosphorylation (CM/24 h). Preincubation of
P19 cells with the HIV/CM did not affect IGF-I-mediated
phosphorylation of GSK-3 and Akt at both 24 and 48 h
time intervals. The only detectable change induced by
HIV/CM was the enhancement of Erk-2 phosphorylation
after the IGF-I treatment. Altogether, these results indi-
cate that HIV/CM is not affecting both basal and IGF-I-
stimulated levels of Akt, ERKs, and GSK-3 phosphory-
lation in differentiated 19 cells.
The IB protein binds to and prevents nuclear translo-
cation of the transcription factor Rel/NFB (Baeuerle and
Baltimore, 1988). The mechanism by which TNFR1 sig-
naling activates NFB involves IB phosphorylation by
IKKs, and subsequent proteosomal degradation of IB
(Zandi et al., 1998). Figure 5 shows that serum-starved,
differentiated P19 cells have detectable levels of phos-
phorylated IB. Following TNF stimulation, levels of
phosphorylated IB increase and remain elevated for at
least 3 h. The same blot probed with antitotal IB anti-
body confirmed lack of expected down-regulation of IB
at later time points following TNF stimulation. When
P19 cells were pretreated for 24 h with IGF-I (50 ng/ml),
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subsequent TNF stimulation resulted in enhanced IB
phosphorylation at 5 and 10 min after the treatment, and
again total IB was not down-regulated. These results
suggest that IGF-I cooperates with TNF in respect to IB
phosphorylation and indicate that the mechanism of IB
degradation is impaired in differentiated P19 neurons.
DISCUSSION
HIV infection often results in neurological disorders of
the central nervous system in a substantial number of
AIDS patients (Gabuzda and Hirsch, 1987). The preva-
stimulated with IGF-I (50 ng/ml). The cell number was evaluated before
the treatment (TO) and at 48 and 96 h following the IGF-I stimulation.
Data represent an average from three experiments. (C) Parental P19,
P19 expressing IGF-IR cDNA (P19/IGF-IR), and P19 cells expressing
antisense to IGF-IR (P19/aslGF-IR) were differentiated with retinoic acid
and subsequently treated with the HIV/CM (dilution 1:5) in the presence
of IGF-I (50 ng/ml). The percentage change in the number of neuronal
processes was evaluated at 24 and 72 h following the treatment. The
results represent percentage change in the average length of neuronal
processes per field over TO (measurement taken before the treatment).
This is an average of two experiments consisting of two 35-mm plates
per point, from which measurements were taken in three separate
microscopic fields (n  12).
FIG. 3. IGF-IR-dependent protection of differentiated neurons from
the HIV/CM. (A) Western blot analysis showing IGF-IR and TNFRI (p55)
protein levels in R600 fibroblasts that express 3 104 IGF-IR molecules
per cell; in parental P19 cells; and in P19 cells stably transduced with
MSCV based retroviral vector expressing either wt human IGF-IR cDNA
(P19/IGF-IR), or antisense IGF-IR (asIGF-IR). Proteins were isolated
from transduced cell populations indicated above and 50 g of each
protein sample was applied to SDS–PAGE gels for Western blot anal-
ysis. After the transfer into nitrocellulose membranes, blots were
probed with anti-IGF-IR antibody (N-20; Santa Cruz) and with anti-
TNFR1 antibody (H-271; Santa Cruz). To control equal loading condi-
tions, the blots were stripped and reprobed with the antibody against
GRB-2, as previously described (Peruzzi et al., 1999). (B) Evaluation of
the growth responses to IGF-I in the condition of anchorage-indepen-
dence. Cell lines indicated above were detached from monolayer
cultures and plated on PolyHema-coated dishes to prevent attachment.
The suspension cultures were left without the treatment (SFM) or were
FIG. 4. Effects of the HIV/CM on immediate signaling responses from
the activated IGF-IR. Western blots were processed with antibodies that
recognize phosphorylated forms of GSK-3, Akt, and MAP kinases
(Erk-1 and Erk-2). All primary antibodies were obtained from Cell
Signaling Technology, New England Labs. Retinoic acid (RA) differen-
tiated P19 cells were starved in serum-free medium for 24 h and were
subsequently incubated with HIV/CM (dilution 1:5) for 24 and 48 h. IGF-I
stimulation (50 ng/ml) was executed in untreated cultures (IGF-I), or in
cultures pretreated with the conditioned medium for 24 or 48 h (HIV/
CM/24 h  IGF) or (HIV/CM/48 h  IGF). Cells which were not
stimulated (SFM) or cells treated exclusively with the conditioned
medium (HIV/CM/24 h) were used as reference samples. Protein ex-
tracts were collected within 15 min following IGF-I stimulation.
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lence of HIV associated dementia (HAD) has been esti-
mated in the early 1990s to be as high as 20–30% of
those patients with advanced HIV disease. It has been
speculated that HAD remains the most common cause of
dementia worldwide among people at ages 40 or less
and is considered a significant independent risk factor
for death due to AIDS (Glass and Johnson, 1996; Price,
1988; Sharer, 1992). The pathogenesis of HAD is believed
to involve the release of toxic substances in the brain by
activated and/or infected mononuclear phagocytes, lead-
ing to neuronal and astrocytic dysfunction and death
(Price, 1988; Price et al., 1988; Thompson et al., 2001).
The proinflammatory cytokine, TNF, released by acti-
vated and/or HIV-1-infected brain macrophages and mi-
croglia, appears to provide a substantial contribution to
neuronal cell damage (Rieckmann et al., 1991; Rimaniol
et al., 1997). In addition to factors promoting neuronal
injury, a decrease in levels/activity of neuronal protective
mechanisms may also contribute to the overall injury
process. In support of this notion, several studies sug-
gest that IGF-I-mediated responses are impaired during
the course of HIV infection (Jain et al., 1998; Laue et al.,
1990), leaving neuronal cells with attenuated defense
mechanism against proapoptotic cytokines and toxic
metabolites. Reduced levels of serum IGF-I have been
observed in HIV-infected patients, particularly those with
wasting syndrome and in children with failure to thrive
(Jain et al., 1998; Laue et al., 1990). As IGF-I is a principal
mediator of the action of human growth hormone, its role
in anabolic effects has prompted studies of IGF-I levels
in HIV-infected patients and the use of both IGF-I and
growth hormone in the treatment of cachectic patients
(Frost et al., 1996; Lo et al., 2001; Mynarcik et al., 1999,
2000). Although some improvements in body mass have
been noted, these studies also suggest partial resis-
tance to the effects of growth hormone and/or IGF-I in the
setting of HIV-wasting syndrome (Jain et al., 1998). De-
creased levels of IGF-I in the central nervous system may
promote neuronal apoptosis in HIV infection, or alterna-
tively, by mechanisms which contribute to IGF-I resis-
tance. The resistance may occur at the level of the
receptor (low expression of the IGF-IR or its mutation), or
FIG. 5. Effects of TNF and IGF-I on IB phosphorylation. (A) Western blots processed with antibodies that recognize phosphorylated (p) or total
(total) IB (Cell Signaling Technology, New England Labs). Retinoic acid (RA) differentiated P19 cells were starved in serum-free medium for 24 h (SFM)
and were subsequently incubated with IGF-I (50 ng/ml) for 24 h (IGF-I 24 h), or were left without treatment (No IGF-I). Subsequently cells were
stimulated with TNF (20 ng/ml) and total proteins were isolated at indicated time points. (B) Densitometric evaluation of the blot depicted in A.
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by a specific attenuation of the critical signaling factors
such as Akt. Some of these effects may be due to the
action of TNF, which has been demonstrated to inhibit
some of the known activities of the IGF-IR and insulin
receptor (IR) in diabetes (Hotamisligil, 1999), and was
shown to inhibit IGF-I-stimulated protein synthesis in
myoblasts (Jain et al., 1998). These TNF-mediated ef-
fects have been suggested to involve serine phosphor-
ylation and partial inactivation of two major signaling
molecules of the IGF system, IRS-I and IRS-2 (Peraldi et
al., 1996; Venters et al., 1999).
In the experimental setting proposed here, cellular
responses to HIV/CM have been initially tested in expo-
nentially growing monolayer cultures of P19 and PC 12
cells. Surprisingly, we observed no significant changes
in the rate of cell proliferation and cell death, suggesting
that the undifferentiated neuronal cell lines are resistant
to the secreted neurotoxic factors from the HIV/CM. In
contrast to the relative resistance of undifferentiated
cells, differentiated neuronal cultures were highly sensi-
tive to the injuries inflicted by the HIV/CM. We observed
a greater proportional decrease in the number of neurite-
like processes compared to the modest decrease in the
cell number. This may imply that cells which lost neuro-
nal processes did not undergo apoptosis or that cell
proliferation occurred despite of the treatment. To avoid
potentially complex issues related to the presence or
absence of apoptosis versus proliferation in neuronal
cultures, we expressed our results in terms of the num-
ber of neurite-bearing cells (PC 12 cells), or by the length
of neurite-like processes per microscopic field (p19
cells). Results presented in this article demonstrate that
differentiated neurons are not capable of maintaining
neuronal processes when exposed to the conditioned
medium from HIV-I-infected macrophages (HIV/CM). Fur-
ther, it is evident that TNF-activating TNFR1 (p55) par-
ticipates in the process of HIV/CM-induced neuronal
degeneration. This observation is in agreement with pre-
vious reports showing neuronal death, evaluated by LDH
release, only in differentiated cultures of NT2N neurons
treated with TNF (Westmoreland et al., 1996).
Since the IGF-IR efficiently rescues differentiated neu-
rons from both HIV/CM and TNF-induced damage of
neuronal processes (Figs. 2 and 3), it is feasible that the
mechanism of its neuroprotective action involves, at
least partially, redirection of the signal from the TNFR1.
Depending on the circumstances, which are not well
characterized, TNFR1 may send contradictory signals in
respect to cell survival: proapoptotic FADD-mediated re-
cruitment of procaspase 8 or antiapoptotic Traf-2-medi-
ated phosphorylation of IB (Natoli et al., 1998). If the
IGF-IR affects TNFR1 signaling on this level, the connec-
tion to procaspase 8 should be attenuated and the acti-
vation of NFB should be enhanced. In this respect our
data demonstrate a strong TNF-mediated phosphoryla-
tion of IB in P19 cells preconditioned by the IGF-I (Fig. 5).
The IGF-IR could also switch TNFR1 into antiapoptotic
mode by facilitating FLIP activity and subsequent inhibi-
tion of caspase 8. Although this possibility has never
been shown for IGF-IR directly, signaling molecules that
are known to be activated by the IGF-IR could do so. This
includes Akt (Panka et al., 2001) and/or Raf activation
(Kataoka et al., 2000). In addition, NFB has been also
shown to facilitate FLIP expression (Micheau et al., 2001;
You et al., 2001), suggesting another possible level of the
synergy between IGF-IR and TNFR1. Importantly, the ma-
jor signaling responses from the IGF-IR, including phos-
phorylation of Akt, MAP kinases, and Gsk-3, are not
attenuated in the presence of HIV/CM. Therefore, neu-
roprotective cross-talk between IGF-I and TNF may
include, in addition to the sustained Akt, ERK2, and
GSK3 phosphorylation, TNFR1-mediated activation of
NFB in this HIV-related experimental setting. This also
indicates that molecular manipulations to increase effec-
tiveness of the IGF-IR system may represent a potential
therapeutic approach to rescue differentiated neurons in
HIV-associated dementia.
MATERIALS AND METHODS
Cell lines
Cell-culture conditions for growth and differentiation of
P19 mouse teratocarcinoma (ATCC No. CRL-1825), and
PC12 rat pheochromocytoma (ATCC No. CRL-1721), were
previously reported (Jones-Villeneuve et al., 1982; Teng et
al., 1993). To induce neuronal differentiation, PC12 cells
plated on poly-D-lysine culture dishes were treated in
serum-free medium with NGF (20 ng/ml). Neuronal pro-
cesses began to appear within the first 24 h following the
treatment and could be observed in culture for at least 10
days. The P19 neuronal differentiation was induced by
retinoic acid (RA) (500 nM; Sigma). The response to RA
treatment required cell aggregation that was spontane-
ously induced when the cells were forced to grow in
suspension. The aggregates were collected, resus-
pended in fresh culture medium (-MEM  7.5% CS 
2.5% FBS), and treated with the RA for an additional 48 h.
Subsequently, large cellular aggregates were dissoci-
ated by trypsinization, and single cells and small cellular
aggregates were plated on poly-D-lysine-coated culture
dishes. Under these conditions, neuronal differentiation
was observed within 48 h after the final plating. Long
neuronal processes were maintained in culture for 2
weeks with the medium changed every second day. To
avoid overgrowth with nondifferentiated cells, RA-treated
cells were cultured either in serum-free medium (-
MEM  0.1% BSA) or in serum-supplemented medium
containing Ara-C (1 M) (cytosine -D-arabino-furano-
side, Sigma). R600 fibroblasts, which express 3  104 of
IGF-IR molecules/cell (Reiss et al., 1998), were used as a
reference sample to monitor the level of IGF-IR expres-
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sion in parental P19 cells and in P19 cultures expressing
IGF-IR cDNA in either sense or antisense orientation.
Preparation of conditioned media from HIV-I-infected
T-lymphocytes
Suspension cultures of supT1 cells were infected with
HIV-1 strain SF162 (or JRFL) with a multiplicity of infection
(m.o.i.) of 0.1. Briefly, the cells were incubated with the
virus inoculum for 2 h at 37°C in serum-free RPMI 1640.
At the end of incubation period, the cells were centri-
fuged at 1000 rpm for 5 min at 4°C. The cell pellet was
suspended in RPMI containing 2% fetal bovine serum,
gentamicin (5 g/ml), and incubated at 37°C. Four-fifths
of the cell supernatant was harvested as conditioned
media on alternate days up to day 24 of infection and
stored in 10 ml aliquots at 80°C. For generation of
virus-free conditioned media, one aliquot of the stored
supernatant was thawed and then centrifuged at 3100
rpm at 4°C for 45 min in a centrifugal filter device
(Biomax 10K NMWL membrane, Millipore Corp., MA).
The filtrate was used as virus-free (evaluated by p24
assay) conditioned medium.
Growth in anchorage-independence
To determine this parameter, quiescent cells were
detached from a culture dish with 0.02% disodium ethyl-
enediamine tetraacetate (EDTA) and seeded on dishes
coated with poly(2-hydroxyethyle methacrylate) [poly-
(HEMA)] (Aldrich, Milwaukee, WI), prepared according to
the methodology previously described (Reiss et al.,
1998). Cells were seeded in SFM at 1  104 cells/cm2
and were treated either with 10% FBS or 50 ng/ml IGF-I or
were left untreated. Twenty-four hours later cell suspen-
sions were collected and dissociated with 0.25% trypsin,
and cells were counted in a Brightline Hemocytometer.
Results represent an average of three experiments and
are expressed as a percentage change in cell number.
Detection of DNA strand breaks
DNA strand breaks were labeled with biotinylated
dUTP (Boehringer Mannheim), using exogenous terminal
deoxynucleotidyl transferase (TDT; Boehringer Mann-
heim). Cells were fixed on ice with a buffered 10% meth-
anol-free formaldehyde (Polyscience, Inc.) for 20 min,
incubated with 70% ethanol for 1 h at 20°C, and
washed 3 with PBS. DNA strand breaks were detected
by in situ labeling of free 3-OH ends on DNA. Fixed cells
were incubated with 50 l of a reaction mixture (5 units
TDT, 2.5 mM CoCl2, 0.2 M potassium cacodylate, 25 mM
Tris–HCl, 0.25% bovine serum albumin, and 0.5 nM bi-
otin-16-dUTP) for 30 min at 37°C and incubated with
staining solution [5 g/ml of fluorescein isothiocyanate
extravidin (FITC), 4 SSC, 0.1% Triton X-100, and 5%
nonfat dry milk] for 30 min at 37°C. DNA strand breaks
were visualized under a fluorescent microscope
equipped with a set of excitation-emission filters for
fluorescein (excitation blue, emission green).
Retroviral transduction
The MSCV.pac and MSCV.neoEB retroviral vectors,
kindly provided by Dr. Hawley (University of Toronto,
Canada), are described elsewhere (Hawley et al., 1994).
The self-inactivating (SIN) version of the MSCV.pac was
engineered by deleting 299 bp in the 3 long terminal
repeat (LTR), as described elsewhere (Yu et al., 1986). A
general cloning strategy was based on PCR-amplified
cDNA fragments of the wild-type IGF-IR cDNAs in the
sense and antisense orientation. The PCR primers con-
taining appropriate restriction sites in overhangs were
previously described (Romano et al., 1999; Valentinis et
al., 2000). Prior to cloning, each amplified fragment was
verified by sequencing (Nucleic Acid Facility at Kimmel
Cancer Center, Thomas Jefferson University, Philadel-
phia, PA).
Western blot analysis
To determine levels of phosphorylated forms of IGF-I-
induced signaling molecules, differentiated cultures of
P19 cells were lysed on ice with 400 l of lysis buffer [(50
mM HEPES); pH 7.5; 150 mM NaCl; 1.5 mM MgCl2; 1 mM
EGTA; 10% glycerol; 1% Triton X-100; 1 mM phenylmeth-
ylsulfonyl fluoride (PMSF); 0.2 mM Na-orthovanadate,
and 10 g/ml aprotinin]. Protein concentration was de-
termined by a Bio-Rad Protein Assay (Bio-Rad, Hercules,
CA), and 50 g of total proteins were separated on a
4–15% gradient SDS–PAGE (Bio-Rad) and transferred
onto nitrocellulose membranes. Blots were blocked with
5% nonfat dry milk in TBST (10 mM Tris–HCl, pH 7.5, 150
mM NaCl, 0.1% Tween 20) and were probed with the
appropriate primary antibodies. Total and phosphory-
lated forms of Akt/PKB, Erk1/Erk2, GSK-3, and IB were
detected by utilizing PhosphoPlus antibody kits obtained
from New England BioLabs, Beverly, MA.
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